MW EG169 articl NS 20160223171404 captis executive search management consulting leadership board services

Taysha Gene Therapies started at outperform with $31 stock price target at Wedbush

MW EG169 articl NS 20160223171404 captis executive search management consulting leadership board services

Taysha Gene Therapies Inc.

Taysha Gene Therapies, Inc.is a patient-centric, clinical-stage gene therapy company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II in 2019 and is headquartered in Dallas, TX.

This is not a CAPTIS article. Originally, it was published here.